DAVID ALTSHULER - 01 Feb 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Global Research and CSO
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
01 Feb 2022
Net transactions value
-$1,171,842
Form type
4
Filing time
03 Feb 2022, 15:06:58 UTC
Previous filing
16 Nov 2021
Next filing
14 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +8,166 +24% $0.000000 41,755 01 Feb 2022 Direct F1
transaction VRTX Common Stock Award $0 +11,628 +28% $0.000000 53,383 01 Feb 2022 Direct F2
transaction VRTX Common Stock Award $0 +12,314 +23% $0.000000 65,697 01 Feb 2022 Direct F3
transaction VRTX Common Stock Options Exercise $403,183 +4,660 +7.1% $86.52* 70,357 02 Feb 2022 Direct
transaction VRTX Common Stock Sale $123,865 -500 -0.71% $247.73 69,857 02 Feb 2022 Direct F4, F5, F6
transaction VRTX Common Stock Sale $31,579 -127 -0.18% $248.65 69,730 02 Feb 2022 Direct F4, F6, F7
transaction VRTX Common Stock Sale $188,477 -754 -1.1% $249.97 68,976 02 Feb 2022 Direct F4, F6, F8
transaction VRTX Common Stock Sale $246,196 -980 -1.4% $251.22 67,996 02 Feb 2022 Direct F4, F6, F9
transaction VRTX Common Stock Sale $226,890 -900 -1.3% $252.10 67,096 02 Feb 2022 Direct F4, F6, F10
transaction VRTX Common Stock Sale $278,498 -1,099 -1.6% $253.41 65,997 02 Feb 2022 Direct F4, F6, F11
transaction VRTX Common Stock Sale $76,338 -300 -0.45% $254.46 65,697 02 Feb 2022 Direct F4, F6, F12

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Stock Option (Right to Buy) Options Exercise $403,183 -4,660 -100% $86.52* 0 02 Feb 2022 Common Stock 4,660 $86.52 Direct F13
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022.
F2 Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022.
F3 Restricted stock unit award that vests in installments beginning on 02/24/2023.
F4 Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
F5 Open market sales reported on this line occurred at a weighted average price of $247.73 (range $247.35 to $248.34).
F6 Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F7 Open market sales reported on this line occurred at a weighted average price of $248.65 (range $248.46 to $249.34).
F8 Open market sales reported on this line occurred at a weighted average price of $249.97 (range $249.61 to $250.33).
F9 Open market sales reported on this line occurred at a weighted average price of $251.22 (range $250.71 to $251.70).
F10 Open market sales reported on this line occurred at a weighted average price of $252.10 (range $251.75 to $252.72).
F11 Open market sales reported on this line occurred at a weighted average price of $253.41 (range $253.05 to $253.99).
F12 Open market sales reported on this line occurred at a weighted average price of $254.46 (range $254.34 to $254.58).
F13 Fully vested.

Remarks:

Exhibit 24 - Power of Attorney